Marilyne Labrie
Impact in
- Immunology top 5%
- Galectins and Cancer Biology
- interferon and immune responses
- Toxin Mechanisms and Immunotoxins
- Oncology top 5%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Glycosylation and Glycoproteins Research 5
- Advanced Biosensing Techniques and Applications 4
- Signaling Pathways in Disease 3
- RNA modifications and cancer 3
- Oncology 16
- PARP inhibition in cancer therapy 9
- Co-authors
- Gordon B. Mills (19 shared papers)Yves St‐Pierre (12 shared papers)Joan S. Brugge (1 shared paper)Ioannis K. Zervantonakis (1 shared paper)Zhenlin Ju (4 shared papers)Wei Zhao (2 shared papers)Guang Peng (1 shared paper)Yang Peng (1 shared paper)
- Journals
- Cancer Research (5 papers)Oncotarget (4 papers)PLoS ONE (4 papers)Journal of Clinical Oncology (2 papers)Cancer Cell (1 paper)
- Partner nations
- CanadaUnited StatesChina
In The Last Decade
Marilyne Labrie
36 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Immunology 529
- Oncology 550
- Cancer Research 198
- Reproductive Medicine 99
- Molecular Biology 786
Countries citing papers authored by Marilyne Labrie
This map shows the geographic impact of Marilyne Labrie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marilyne Labrie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marilyne Labrie more than expected).
Fields of papers citing papers by Marilyne Labrie
This network shows the impact of papers produced by Marilyne Labrie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marilyne Labrie. The network helps show where Marilyne Labrie may publish in the future.
Co-authors
The 25 scholars most cited alongside Marilyne Labrie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness Hit paper breakdown → | 2018 | 427 |
| 2 | Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer Hit paper breakdown → | 2022 | 212 |
| 3 | 2018 | 160 | |
| 4 | 2014 | 62 | |
| 5 | 2012 | 57 | |
| 6 | 2016 | 41 | |
| 7 | 2017 | 38 | |
| 8 | 2013 | 38 | |
| 9 | 2014 | 34 | |
| 10 | 2020 | 29 | |
| 11 | 2014 | 28 | |
| 12 | 2022 | 26 | |
| 13 | 2018 | 25 | |
| 14 | 2021 | 23 | |
| 15 | 2015 | 23 | |
| 16 | 2015 | 22 | |
| 17 | 2015 | 19 | |
| 18 | 2013 | 15 | |
| 19 | 2014 | 14 | |
| 20 | 2019 | 14 |
About Marilyne Labrie
Marilyne Labrie is a scholar working on Molecular Biology, Oncology, Immunology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 38 papers that have together received 1.4k indexed citations. Recurring topics across this work include Galectins and Cancer Biology (11 papers), PARP inhibition in cancer therapy (9 papers), Cancer Genomics and Diagnostics (5 papers), Toxin Mechanisms and Immunotoxins (5 papers), Glycosylation and Glycoproteins Research (5 papers), Advanced Biosensing Techniques and Applications (4 papers), Signaling Pathways in Disease (3 papers) and RNA modifications and cancer (3 papers). The work is most often cited by research in Immunology (529 citations), Oncology (550 citations), Cancer Research (198 citations), Reproductive Medicine (99 citations) and Molecular Biology (786 citations). Marilyne Labrie has collaborated with scholars based in Canada, United States and China. Frequent co-authors include Gordon B. Mills, Yves St‐Pierre, Joan S. Brugge, Ioannis K. Zervantonakis, Zhenlin Ju, Wei Zhao, Guang Peng, Yang Peng, Timothy A. Yap and Lulu Wang. Their work appears in journals such as Cancer Research, Oncotarget, PLoS ONE, Journal of Clinical Oncology and Cancer Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.